ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease,
Growth Capitalist (https://growthcapitalist.com/2018/06/real-world-study-suggests-canagliflozin-does-not-increase-risk-of-below-knee-amputation-in-people-with-type-2-diabetes/)
ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease,